Next Article in Journal
The Mediating Role of Compassion between Social Job Resources, and Healthy Healthcare Professionals: A Cross-Sectional Study with Gender Perspective
Previous Article in Journal
Tobacco Use and Exposure to Environmental Tobacco Smoke amongst Pregnant Women in the United Arab Emirates: The Mutaba’ah Study
Previous Article in Special Issue
Public Health Implications of Cannabis Legalization: An Exploration of Adolescent Use and Evidence-Based Interventions
 
 
Article

Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products

1
Division of Psychology, School of Education and Social Sciences, University of the West of Scotland, Paisley PA1 2BE, UK
2
Medical Cannabis Research Group, Imperial College London, London SW7 2BX, UK
3
Sapphire Medical Clinics, London W1G 9PF, UK
*
Author to whom correspondence should be addressed.
Academic Editors: Paul B. Tchounwou and Marta Tremolada
Int. J. Environ. Res. Public Health 2022, 19(12), 7499; https://doi.org/10.3390/ijerph19127499
Received: 19 April 2022 / Revised: 16 June 2022 / Accepted: 17 June 2022 / Published: 19 June 2022
(This article belongs to the Special Issue Health Effects of Cannabis Use)
Cannabis-based medicinal products (CBMPs) are prescribed with increasing frequency. This study aimed to investigate the perceived stigma attached to patients prescribed CBMPs in the UK to establish its prevalence. A qualitative survey was developed by an expert multidisciplinary group and data were collected via Qualtrics. In total, 2319 patients on CBMP therapy were invited to take part in this study. 450 (19.4%) participants completed the questionnaire. In total, 81.3% (n = 366), 76.9% (n = 346), and 61.3% (n = 276) of participants reported feeling very comfortable or comfortable telling friends, family, and medical professionals, respectively, about their treatment. Participants thought that friends (n = 372; 82.7%) and family (n = 339; 75.3%) were very approving or somewhat approving of their CBMP prescription. However, participants thought that only 37.8% (n = 170) of healthcare professionals and 32.9% (n = 148) of society in general were very approving or somewhat approving of their CBMP prescription. 57.1% (n = 257), 55.3% (n = 249), and 40.2% (n = 181) of participants were afraid of what the police or criminal justice system, other government agencies, and healthcare professionals might think about their treatment. This study highlights those patients treated with CBMPs experience a high prevalence of perceived stigma from many corners of society. Future work should be undertaken to explore strategies to reduce perceived stigma at an individual and community level to avoid discrimination of patients, likely increasing appropriate access. View Full-Text
Keywords: cannabis; medical cannabis; cannabinoids; social stigma; health services accessibility cannabis; medical cannabis; cannabinoids; social stigma; health services accessibility
Show Figures

Figure 1

MDPI and ACS Style

Troup, L.J.; Erridge, S.; Ciesluk, B.; Sodergren, M.H. Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products. Int. J. Environ. Res. Public Health 2022, 19, 7499. https://doi.org/10.3390/ijerph19127499

AMA Style

Troup LJ, Erridge S, Ciesluk B, Sodergren MH. Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products. International Journal of Environmental Research and Public Health. 2022; 19(12):7499. https://doi.org/10.3390/ijerph19127499

Chicago/Turabian Style

Troup, Lucy J., Simon Erridge, Beata Ciesluk, and Mikael H. Sodergren. 2022. "Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products" International Journal of Environmental Research and Public Health 19, no. 12: 7499. https://doi.org/10.3390/ijerph19127499

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop